Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.

被引：12
|
作者：
Garcia-Manero, Guillermo
Daver, Naval Guastad
Xu, Jin
Chao, Mark
Chung, Trisha
Tan, Anderson
Wang, Vivian
Wei, Andrew
Vyas, Paresh
Sallman, David Andrew
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[3] Alfred Hosp, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Univ Oxford, MRC Mol Haematol Unit, Oxford, England
[6] Univ Oxford, Oxford Biomed Res Ctr, Oxford, England
[7] Oxford Univ Hosp, Oxford, England
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7055
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777)
    Santini, V.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J. F.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D. V.
    Ades, L.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 3
  • [42] Pevonedistat (P) plus azacitidine (A) vs A alone in higher-risk myelodysplastic syndromes (HR-MDS): efficacy and safety results from study P-2001 (NCT02610777)
    Giagounidis, A.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Lopez, Font P.
    Zeidner, J. F.
    Campelo, Diez M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhou, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D., V
    Ades, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 30 - 30
  • [43] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
    Giagounidis, A.
    Ades, L.
    Watts, J.
    Radinoff, A.
    Arnan Sangerman, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Bell, J.
    Friedlander, S.
    Faller, D. V.
    Sekeres, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
  • [44] Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes
    Zeidner, Joshua F.
    Mazerolle, Flora
    Bell, Jill A.
    Cain, Lauren E.
    Faller, Douglas V.
    Dalal, Mehul
    Regnault, Antoine
    Fram, Robert J.
    BLOOD, 2020, 136
  • [45] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [46] A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
    Donnellan, William Bruce
    Diez-Campelo, Maria
    Heuser, Michael
    Ritchie, Ellen K.
    Skolnik, Jeffrey
    Font, Patricia
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
  • [48] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [49] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
    Thepot, Sylvain
    Ben Abdelali, Raouf
    Chevret, Sylvie
    Renneville, Aline
    Beyne-Rauzy, Odile
    Prebet, Thomas
    Park, Sophie
    Stamatoullas, Aspasia
    Guerci-Bresler, Agnes
    Cheze, Stephane
    Tertian, Gerard
    Choufi, Bachra
    Legros, Laurence
    Bastie, Jean Noel
    Delaunay, Jacques
    Chaury, Marie Pierre
    Sanhes, Laurence
    Wattel, Eric
    Dreyfus, Francois
    Vey, Norbert
    Chermat, Fatiha
    Preudhomme, Claude
    Fenaux, Pierre
    Gardin, Claude
    HAEMATOLOGICA, 2016, 101 (08) : 918 - 925
12345